Skip to Main Content

Author Details

Ian G Mills
Queen's University Belfast
1997
183
54
PMIDPaper TitleJournal TitlePublished Year
36815702The role of CaMKK2 in Golgi-associated vesicle trafficking.Biochem Soc Trans2023
37628903Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.Int J Mol Sci2023
36949059CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.Sci Rep2023
37410655Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?BJU Int2023
37332616Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.Oncoimmunology2023
34127801Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24.Prostate Cancer Prostatic Dis2022
35708495O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition.Glycobiology2022
35348747VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in Prostate Cancer.Mol Cancer Res2022
36353660Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer.Eur Urol Open Sci2022
35948708Spatially resolved clonal copy number alterations in benign and malignant tissue.Nature2022
35075123Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.Nat Commun2022
35256616Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.Nat Commun2022
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
35085228The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study.PLoS Med2022
35302608Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.Mol Cancer Res2022
33472950O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene?Mol Cancer Res2021
35474657Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.BJUI Compass2021
33828258Vascular normalisation as the stepping stone into tumour microenvironment transformation.Br J Cancer2021
33547161ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.Cancer Res2021
33623038Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nat Commun2021
33734461Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.Prostate2021
33888445A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease.Eur Urol Oncol2021
33608585Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.Sci Rep2021
33723363Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.Prostate Cancer Prostatic Dis2021
33525365Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges.Cancers (Basel)2021
34725334CaMKK2 facilitates Golgi-associated vesicle trafficking to sustain cancer cell proliferation.Cell Death Dis2021
34660272The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects.Front Oncol2021
34592899Inhibition of CDK9 activity compromises global splicing in prostate cancer cells.RNA Biol2021
33969359IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits.Discov Oncol2021
34155340Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.Br J Cancer2021
33420416Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate Cancer Prostatic Dis2021
32450824Independence of HIF1a and androgen signaling pathways in prostate cancer.BMC Cancer2020
34337468Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification.Eur Urol Open Sci2020
31874245miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.Cancer Lett2020
31779479Methodology for the at-home collection of urine samples for prostate cancer detection.Biotechniques2020
33046784Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells.Sci Rep2020
33003551Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer.Cancers (Basel)2020
32743555Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.NAR Cancer2020
32573466The role of the androgen receptor as a driver and mitigator of cellular stress.J Mol Endocrinol2020
32641865Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.Br J Cancer2020
32611550Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.Mol Cancer Res2020
32170918Propagation of human prostate tissue from induced pluripotent stem cells.Stem Cells Transl Med2020
32514134The effect of sample size on polygenic hazard models for prostate cancer.Eur J Hum Genet2020
32229180Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.J Mol Diagn2020
30679434IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.Nat Commun2019
30237440A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.Oncogene2019
31551480Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.Sci Rep2019
31450747The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing.Cancers (Basel)2019
31395667The β<sub>2</sub>-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.Mol Cancer Res2019
31337863Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer.Sci Rep2019
  • 1 - 50 of 183

Recommended Authors

Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Career Start Year 2012
Number of shared co-authors 12
Ren?? B??ttcher
Universitat Pompeu Fabra
Career Start Year 2012
Number of shared co-authors 4
Jin-Yih Low
Fred Hutchinson Cancer Center
Career Start Year 2010
Number of shared co-authors 7
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 14
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 20
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 12
Sungyong You
Cedars-Sinai Medical Center
Career Start Year 2008
Number of shared co-authors 15
Changmeng Cai
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Career Start Year 2006
Number of shared co-authors 12
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 24
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 5
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2004
Number of shared co-authors 18
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 11
Adam Spencer
University of Virginia
Career Start Year 2004
Number of shared co-authors 0
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 3
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 6
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 21
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 18
Amina Zoubeidi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 27
Leena Latonen
Foundation for the Finnish Cancer Institute
Career Start Year 1999
Number of shared co-authors 7
Kristiina Iljin
VTT Technical Research Centre of Finland Ltd
Career Start Year 1999
Number of shared co-authors 2
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 17
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 4
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 9
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 45
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 54
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 44
Suzanne Carreira
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 17
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 35
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1987
Number of shared co-authors 16
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Career Start Year 1981
Number of shared co-authors 24

Collaborators

David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 40
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Co-authored papers 23
Charlie E Massie
University of Cambridge
Co-authored papers 22
Alastair D Lamb
University of Oxford
Co-authored papers 19
Alfonso Urbanucci
Northwestern University Feinberg School of Medicine Chicago
Co-authored papers 15
Ole A Andreassen
Oslo University Hospital & Institute of Clinical Medicine, University of Oslo
Co-authored papers 14
Freddie C Hamdy
University of Oxford
Co-authored papers 14
Henrik Gr??nberg
Karolinska Institute
Co-authored papers 12
Anders M Dale
University of California San Diego
Co-authored papers 12
Hayley C Whitaker
University College London
Co-authored papers 11
Fredrik Wiklund
Co-authored papers 10
Helen J Ross
Mayo Clinic
Co-authored papers 9
Wesley K Thompson
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH)
Co-authored papers 9
Andy G Lynch
University of St Andrews
Co-authored papers 9
Chun Chieh Fan
University of California San Diego
Co-authored papers 7
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 6
Ruth C Travis
Co-authored papers 6
Srdjan Djurovic
Oslo University Hospital
Co-authored papers 6
Nikolai Engedal
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 6
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 6
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 5
Lars Egevad
Karolinska Institute
Co-authored papers 5
Ladan Fazli
University of British Columbia
Co-authored papers 5
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Co-authored papers 5
Vincent J Gnanapragasam
University of Cambridge
Co-authored papers 5
Johan Lindberg
Karolinska Institute
Co-authored papers 5
Johanna Schleutker
Institute of Biomedicine, University of Turku
Co-authored papers 5
Mark J Dunning
The Medical School, The University of Sheffield
Co-authored papers 5
Yunpeng Wang
University of Oslo, Regeneron Pharmaceuticals
Co-authored papers 5
Børge G Nordestgaard
Co-authored papers 5
Release 1.2